Astellas, UCB to develop arthritis drug in Japan
TOKYO |
TOKYO Feb 1 (Reuters) - Astellas Pharma Inc said on Wednesday it and Belgian pharmaceutical group UCB will jointly develop and sell the rhematoid arthritis drug Cimzia, or certolizumab pegol, in Japan. (Reporting by Mayumi Negishi)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters